Sunitinib or sorafenib as neoadjuvant therapy may not improve the survival outcomes of renal cell carcinoma with tumor thrombus

Authors :: B. Dong
W. Cai
W. Kong
Y. Chen
M. Li
J. Huang
Y. Huang
W. Xue
J. Zhang
Source :: European Urology Supplements. 17:e19
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: Sorafenib
Oncology
medicine.medical_specialty
business.industry
Sunitinib
Urology
medicine.medical_treatment
medicine.disease
Tumor thrombus
Renal cell carcinoma
Internal medicine
medicine
business
Neoadjuvant therapy
medicine.drug

Full Text Access

Tools